LID.L Regulatory News (LID)

31 Jul 2007 12:45

For immediate release 31 July 2007 LiDCO Group Plc ('the Company') Share Transfer

On 31 July 2007, Dr. Terry O'Brien, Chief Executive and director of the Company, informed the Company that today he has sold 1,451,163 ordinary shares of 0.5p each in the Company at 10.75 pence per share. Dr O'Brien's pension fund subsequently bought today 1,451,163 ordinary shares of 0.5p each at 10.75 pence per share.

As a consequence of this sale and purchase, Dr O'Brien's interest in the share capital of the Company remains at 10,229,577 shares representing approximately 8.64% of the Company's issued share capital.

- ENDS -

For more information please contact:

LiDCO Group Plc Tel: +44 (0)20 7749 1500 Terry O'Brien - Chief Executive Buchanan Communications Tel: +44 (0)20 7466 5000 Tim Anderson, James Strong Notes for EditorsAbout LiDCO Group Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base.

The Company's manufacturing facility is in Hoxton, London N1 and its current products are:

- LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;

- LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.